SynthesisInfluenza and other respiratory viruses2010
Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age.
Synthesis in Influenza and other respiratory viruses, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Vaccines for preventing influenza in healthy children.The Cochrane database of systematic reviews · 2018Pooled it
- A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children.Human vaccines & immunotherapeutics · 2016Pooled it
- Vaccines for preventing influenza in healthy children.The Cochrane database of systematic reviews · 2012Pooled it
- Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.Clinical and experimental immunology · 2021Trial
- Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial.The Lancet. Global health · 2016Trial
- The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine.Human vaccines & immunotherapeutics · 2015Trial
- Trial
- Trial
- Next-generation intranasal influenza vaccines: mechanisms, platforms, and translational progress.Frontiers in immunology · 2026Review
- Age-dependent immune landscapes affect influenza vaccine effectiveness and guide precision strategies.Frontiers in immunology · 2026Review
- Review
- Tissue-specific sex differences in pediatric and adult immune cell composition and function.Frontiers in immunology · 2024Article
- Safety and Efficacy of Spray Intranasal Live Attenuated Influenza Vaccine: Systematic Review and Meta-Analysis.Vaccines · 2021Review
- Successes and Failures of the Live-attenuated Influenza Vaccine: Can We Do Better?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Understanding influenza vaccine perspectives and hesitancy in university students to promote increased vaccine uptake.Heliyon · 2019Article
- Immune responses after live attenuated influenza vaccination.Human vaccines & immunotherapeutics · 2018Review
- Development of high-yield influenza B virus vaccine viruses.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- A Single Mutation at PB1 Residue 319 Dramatically Increases the Safety of PR8 Live Attenuated Influenza Vaccine in a Murine Model without Compromising Vaccine Efficacy.Journal of virology · 2015Article
- Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.Journal of virology · 2015Article
- Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment.GMS health technology assessment · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been suggested that live attenuated influenza vaccine (LAIV) may be less effective in older individuals because of prior wild-type influenza infections. LAIV is currently approved in the United States, South Korea and Hong Kong for individuals 2-49 years of age.
objectiveTo examine data from previously published pediatric studies to determine the efficacy of LAIV in various age groups.
methodsFour studies in which the subject age range exceeded 36 months were identified: one 2-year study comparing LAIV with placebo and three 1-year studies comparing LAIV with trivalent inactivated influenza vaccine (TIV). Efficacy against any strain regardless of antigenic similarity to vaccine was analyzed by age; age groups were based on the study design and sample size. A logistic regression model was used to assess whether age, as a continuous variable, was an effect modifier on LAIV efficacy.
resultsThe efficacy of LAIV did not vary with age in children aged 15-84 months compared with placebo or in children aged 6 months to 17 years compared with TIV.
conclusionsThe available data from prospective, randomized studies in children does not support the concept that prior repeated exposure to influenza, either through wild-type infection or vaccination with live, attenuated or inactivated vaccines, reduces the efficacy of LAIV compared with placebo or TIV. The decreased immunologic responses to LAIV reported in older individuals or those with pre-existing immunity do not appear to translate into reduced protection from influenza in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.